Medios AG announced the closure of its Aschaffenburg facility, a wholly owned subsidiary of Medios Solutions Aschaffenburg GmbH, as part of an optimization of its manufacturing network. The company is consolidating patient-specific production at its remaining locations across Germany, with manufacturing already relocated and supplies to pharmacies and hospitals fully guaranteed. The Aschaffenburg site accounted for approximately 10% of the Medios Group’s German production volume, and the closure affects 32 employees, for whom Medios is seeking fair compensation.
The decision comes as the business of patient-specific formulations experiences sustained margin pressure, particularly due to price regulatory adjustments. Medios is countering this with efficiency measures under its Operational Excellence Program. In Germany, the company previously operated a network of six GMP (Good Manufacturing Practice) facilities for patient-specific therapies. The Aschaffenburg site had been operating at below-average profitability amid declining capacity utilization, making continued economic operation unfeasible. Structural renovation work required at the site accelerated the implementation of the closure.
Thomas Meier, CEO of Medios AG, stated, “With a view to ensuring a reliable supply for our customers and maintaining capacity utilization at all sites, we are now optimizing our successful regional presence strategy and consistently developing it further. With Mannheim and Stuttgart, we have two high-performing Medios sites in southern Germany, ensuring that a reliable supply is maintained.”
This move is significant for the pharmaceutical supply chain and the industry at large, as it reflects the challenges faced by specialty pharmaceutical companies in managing regulatory pressures and rising costs. The consolidation may lead to increased efficiency but also highlights the vulnerability of smaller production sites. For pharmacies and hospitals, the guarantee of continued supply is critical, though the long-term impact on pricing and availability remains to be seen. The closure also underscores the importance of regional optimization strategies in maintaining profitability while meeting stringent GMP standards.
Medios AG is a leading provider of Specialty Pharma in Europe, operating locations in Germany, the Netherlands, Belgium, and Spain. The company is listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and is included in the SDAX selection index. More information can be found at www.medios.group.
Key upcoming events for Medios in 2026 include the Half-Year Financial Report on August 12, the Berenberg and Goldman Sachs 15th German Corporate Conference from September 21 to 23 in Munich, the Medios Capital Markets Day on September 28/29 in Breda, and the Quarterly Statement as of September 30 on November 10. The original press release is available at www.newmediawire.com.
